News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sagent Pharmaceuticals, Inc. Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials


5/17/2012 9:49:05 AM

SCHAUMBURG, Ill., May 17, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Irinotecan Injection, the generic form of the chemotherapy drug Camptosar®, in two latex free, preservative free single dose vials. According to IMS data for the twelve-months ended March 2012, the U.S. market for Irinotecan approximated $28 million. As with all products in Sagent's portfolio, Irinotecan features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES